Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon De Vries-Brilland

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|December 24, 2025
A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with PembrolizumabDan-Thanh Christine Nguyen, Zineb Hamilou, Evelyne Bonnardeaux, et al.
Clinical Genitourinary Cancer|May 22, 2019
Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the LiteratureManon de Vries-Brilland, Baptiste Sionneau, Caroline Dutriaux, et al.
The Oncologist|April 5, 2022
Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study)Cassandre Gluszak, Manon de Vries-Brilland, Valérie Seegers, et al.
Biomedicines|January 8, 2025
Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic DataElena Spirina Menand, Manon De Vries-Brilland, Leslie Tessier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2024
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohortJérémie Naffrichoux, Pierre Poupin, William Pouillot, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|December 24, 2025
A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with PembrolizumabDan-Thanh Christine Nguyen, Zineb Hamilou, Evelyne Bonnardeaux, et al.
Clinical Genitourinary Cancer|May 22, 2019
Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the LiteratureManon de Vries-Brilland, Baptiste Sionneau, Caroline Dutriaux, et al.
The Oncologist|April 5, 2022
Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study)Cassandre Gluszak, Manon de Vries-Brilland, Valérie Seegers, et al.
Biomedicines|January 8, 2025
Learning to Train and to Explain a Deep Survival Model with Large-Scale Ovarian Cancer Transcriptomic DataElena Spirina Menand, Manon De Vries-Brilland, Leslie Tessier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Journal for Immunotherapy of Cancer|November 7, 2023
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinomaManon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2024
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohortJérémie Naffrichoux, Pierre Poupin, William Pouillot, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
Pageof 1